LABS MediPharm Labs

Европейская фармацевтическая компания STADA вступает в эксклюзивное партнерство по медицинскому каннабису с MediPharm Labs

Европейская фармацевтическая компания STADA вступает в эксклюзивное партнерство по медицинскому каннабису с MediPharm Labs
EN
08/10/2020

Underlying

LABSMediPharm Labs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediPharm Labs

 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Ov...

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue FY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025Company remains virtually debt-free, with outright ownership of two production facilitiesManagement to Host Conference Call / Webcast on March 30th, 2026, at 10:00 am ET TORONTO, March 30, 2026 (GLOBE NEWSWIRE...

March 30, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 F...

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026. MediPharm Labs executive management team will also host a conference call and webcast o...

March 25, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; C...

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that David Pidduck will be stepping down from his role as the Company's Chief Executive Officer, effective January 23rd, 2026. The Board of Directors (the "Board") has appointed Greg Hunter, the Company's Chief Financial Officer, as Interim Chief Executive Officer, wh...

January 19, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the signing of a definitive supply agreement with Remidose Aerosols Inc. (“Remidose”) for the shipment of GMP-certified medicinal cannabis products to Costa Rica. “MediPharm Labs’ proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannab...

January 13, 2026 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportuni...

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order  to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the "Order")....

December 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch